However, data showed that IL-5 blockades such as mepolizumab (a fully humanized anti-IL-5 monoclonal antibody) could only partially reduce tissue eosinophilia in the esophagus, but it did not reach the primary end point of histological standard (less than 5 eosinophils/high-power field) in clinical trials.81,82 Therefore, the usage of anti-IL-5 antibodies in treating EoE requires more examination. This evidence concerns the gene IL5 and Increased total eosinophil count.